• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25471 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     National Institute for Health and Care Excellence (NICE) Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults. NICE HealthTech guidance 738
2025     Austrian Institute for Health Technology Assessment (AIHTA) Drug-coated balloon catheter for the treatment of urethral strictures
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (giant cell arteritis) – Addendum to Project A25-66]
2025     WorkSafeBC External trigeminal nerve stimulation (e-TNS) in treating and preventing migraine headaches
2025     National Institute for Health and Care Excellence (NICE) Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE HealthTech guidance 737
2025     Austrian Institute for Health Technology Assessment (AIHTA) Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Addendum to Project A25-67]
2025     WorkSafeBC Platelet rich plasma (PRP) in treating post-fracture ankle pain
2025     NIHR Health Technology Assessment programme Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study
2025     Austrian Institute for Health Technology Assessment (AIHTA) One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deutivacaftor/tezacaftor/vanzacaftor (cystic fibrosis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     WorkSafeBC Hypertension and firefighting
2025     NIHR Health Technology Assessment programme Multi-cancer early detection tests for general population screening: a systematic literature review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Leadless cardiac pacemakers
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beremagene geperpavec (dystrophic epidermolysis bullosa) – Assessment according to §35a (para. 1, sentence 11)]
2025     WorkSafeBC Firefighting and Hodgkins lymphoma
2025     NIHR Health Services and Delivery Research programme Peer support for adult social care in prisons in England and Wales: a mixed-methods rapid evaluation
2025     Austrian Institute for Health Technology Assessment (AIHTA) Temporary nitinol implantation for the treatment of benign prostatic hyperplasia
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for total knee replacement]
2025     WorkSafeBC Use of supplements to treat patients diagnosed with sciatica
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to managing people with cervical cancer]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Best group interventions for perpetrators of intimate partner violence]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis]
2025     WorkSafeBC COVID-19 vaccine and systemic lupus erythematosus (SLE)
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery]
2025     WorkSafeBC Cervical disc herniation and cervical spine degeneration
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Lipedema]
2025     WorkSafeBC Osteoarthritis of the knee and foot orthoses
2025     Technology Assessment at SickKids (TASK) A micro-costing and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of migraine in adults]
2025     WorkSafeBC Effect of ropinirole on patients with myoclonic dystonia: 2025 update
2025     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of elranatamab (Elrexfio)]
2025     NIHR Health Technology Assessment programme Implementation and use of technology-enabled remote monitoring for chronic obstructive pulmonary disease: a rapid qualitative evaluation
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Naloxone hydrochloride kits - stability and storage]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II; Hunter syndrome)
2025     Canada’s Drug Agency (CDA-AMC) Automated chest compression devices
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)
2025     Canada’s Drug Agency (CDA-AMC) Dihydropyrimidine dehydrogenase deficiency testing for patients treated with 5-fluorouracil and capecitabine
2025     Canary Health Service [FT-Raman spectroscopy with data analysis using machine learning for the diagnosis of platinum-resistant ovarian cancer]
2025     Adelaide Health Technology Assessment (AHTA) Newborn bloodspot screening for glycogen storage disease, Type II (GSD II; Pompe disease)
2025     Canada’s Drug Agency (CDA-AMC) Myoelectric and microprocessor-enabled prostheses
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Blood determination of N-terminal propeptide of procollagen type 1 (P1NP) by electrochemiluminescence immunoassay (ECLIA)]
2025     Canada’s Drug Agency (CDA-AMC) Flexible dentures for edentulism
2025     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for the treatment of people with symptomatic severe aortic stenosis who are at low surgical risk
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Pharmacological treatment of migraine]
2025     Penn Medicine Center for Evidence-based Practice (CEP) Tools for predicting imminent death
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delgocitinib (moderate to severe chronic hand eczema) – benefit assessment according to §35a Social Code Book V]
2025     Canary Health Service [Tumor treating fields (TTFields) therapy in people with newly diagnosed glioblastoma]
2025     NIHR Health Technology Assessment programme Brief psychodynamic-interpersonal therapy for adults with a history of self-harm: the SafePIT RCT
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2025     Scottish Health Technologies Group (SHTG) Artificial intelligence-assisted clinician review of chest X-rays for suspected lung cancer
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (DLBCL, third line) - Benefit assessment according to §35a Social Code Book V]
2025     HTA South [Observation after mild head injury in patients on anticoagulation therapy: a systematic review and assessment of medical, economical and ethical aspects]
2025     National Institute for Health and Care Excellence (NICE) Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1110
2025     Canada’s Drug Agency (CDA-AMC) Point-of-care ultrasound for guided central venous catheter insertion compared to the landmark method
2025     HTA South [Vaporization with green laser for benign prostatic hyperplasia: a systematic review and assessment of medical, economic, ethical and organisational aspects]
2025     NIHR Health Technology Assessment programme Eradication of Helicobacter pylori for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT
2025     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal). NICE technology appraisal guidance 1112
2025     NIHR Health and Social Care Delivery Program Meeting the needs of women in the perinatal period, who use or are in treatment for using drugs: a mixed-methods systematic review
2025     National Institute for Health and Care Excellence (NICE) Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal). NICE technology appraisal guidance 1111
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fluoroscopic or endoscopic evaluation of dysphagia in adults]
2025     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 1109
2025     National Institute for Health and Care Excellence (NICE) Cabotegravir for preventing HIV-1 in adults and young people. NICE technology appraisal guidance 1106
2025     Ontario Health Magnetic resonance-guided focused ultrasound neurosurgery for treatment-refractory obsessive-compulsive disorder
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposures and asthma and COPD]
2025     National Institute for Health and Care Excellence (NICE) Delgocitinib for treating moderate to severe chronic hand eczema. NICE technology appraisal guidance 1107
2025     Ontario Health Noninvasive vagus nerve stimulation for cluster headache and migraine
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elafibranor (primary biliary cholangitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Non-pharmacological interventions, other than psychosocial ones, for youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2025     National Institute for Health and Care Excellence (NICE) Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1108
2025     Ontario Health Indocyanine green fluorescence imaging for colorectal surgery
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zolbetuximab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-negative) – Assessment in accordance with § 35a Social Code Book (SGB) V (1), Sentence 11]
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025     NIHR Health Services and Delivery Research programme Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025     National Institute for Health and Care Excellence (NICE) Low-energy contact X-ray brachytherapy for rectal cancer. NICE HealthTech guidance 763
2025     Ontario Health Percutaneous vertebroplasty and balloon kyphoplasty for painful osteoporotic vertebral compression fractures
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Meropenem/vaborbactam (bacterial infections, several therapeutic indications) - Assessment in accordance with § 35a (1c) Social Code Book (SGB) V ]
2025     NIHR Health Technology Assessment programme Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Prevention of hypersensitivity reactions to intravascular contrast media during medical imaging in adults]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Cardiac ultrasound: current practices]
2025     Agenzia nazionale per i servizi sanitari regionali (Agenas) Robotic surgery systems in general surgery, gynecology, and urology
2025     Ontario Health DNA methylation-based classification for central nervous system tumours
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy, effectiveness, and economic impact of birth centers as an alternative to low-risk delivery care (at the onset of labor) in a hospital setting]
2025     Ontario Health Home-based heated humidified high-flow therapy for respiratory conditions
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – Second addendum to Project H23-03]
2025     National Institute for Health and Care Excellence (NICE) Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025     Basque Office for Health Technology Assessment (OSTEBA) [3D printing in traumatology, cardiology, vascular surgery, maxillofacial surgery, neurosurgery, joint injuries, and bone repair]
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025     The Danish Health Technology Council (DHTC) [The use of point of care tests (POCT) for elderly patients at home]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intestinal ultrasound in inflammatory bowel disease: diagnostic effectiveness, cost-effectiveness and patient and health professional perspectives]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) – Addendum to Project A25-87]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025     NIHR Health Services and Delivery Research programme Improving the experience of health services for trans and gender-diverse young people and their families: an exploratory qualitative study